You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰森製藥(03692.HK)與NiKang Therapeutics訂立獨家許可協議
阿思達克 05-04 03:26
翰森製藥(03692.HK)公布,與NiKang Therapeutics訂立獨家許可協議。據此,公司獲獨家許可於中國(包括香港、澳門及台灣)開發及商業化NKT2152用於腫瘤的治療,並將支付1,500萬美元首付款及最多2.03億美元的開發、註冊及基於銷售的商業化里程碑潛在付款,以及基於淨銷售額的分級特許權使用費。 目前,NKT2152正開展1/2期劑量遞增及擴展試驗,旨在評估對晚期透明細胞腎細胞癌患者的安全性、耐受性、藥代動力學、藥效學及臨床活性。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account